Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells
Liver cancer: A new route to fighting drug resistance Inhibiting the activity of a protein known as EphA2 may help overcome the development of drug resistance during treatment of hepatocellular carcinoma, the most common form of liver cancer. Resistance often develops to sorafenib, the main drug tre...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2020-03-01
|
| Series: | Experimental and Molecular Medicine |
| Online Access: | https://doi.org/10.1038/s12276-020-0404-2 |